The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Alesenko A.V.

Emanuel Institute of Biochemical Physics of RAS, Moscow, Russia

Bachurin S.O.

Karatasso Yu.O.

Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia

Korotaeva A.A.

Emanuel Institute of Biochemical Physics, Russian Academy of Sciences, Moscow, Russia

Shevzova E.F.

Institute of Physiologically Active Substances, Russian Academy of Sciences, Chernogolovka, Russia

Shingarova L.N.

Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia

Dimebon correction of changes in phospholipid composition induced by tumor necrosis factor-alpha in experement

Authors:

Alesenko A.V., Bachurin S.O., Karatasso Yu.O., Korotaeva A.A., Shevzova E.F., Shingarova L.N.

More about the authors

Read: 895 times


To cite this article:

Alesenko AV, Bachurin SO, Karatasso YuO, Korotaeva AA, Shevzova EF, Shingarova LN. Dimebon correction of changes in phospholipid composition induced by tumor necrosis factor-alpha in experement. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(8):91‑97. (In Russ.)
https://doi.org/10.17116/jnevro201811808191

Recommended articles:
Identification of depression biomarkers: Prospects for use in clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):51-55
Comparative analysis of the placental proteome in normal and severe preeclampsia. Russian Bulletin of Obstetrician-Gynecologist. 2025;(5):5-14

References:

  1. Tarkowski E. Cytokines in dementias. Curr Drug Targets Inflamm, Allergy. 2002;1(2):193-200. https://doi.org/10.2174/1568010023344670
  2. Montgomery SL, Bowers WJ. Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system. J Neuroimmune Pharmacol. 2012;7(1):42-59. https://doi.org/10.1007/s11481-011-9287-2
  3. Arvin B, Neville LF, Barone FC, Feuerstein GZ. The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev. 1996;20(3):445-452. https://doi.org/10.1016/0149-7634(95)00026-7
  4. Clark IA, Alleva LM, Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther. 2010;128:519-548. https://doi.org/10.1016/j.pharmthera.2010.08.007
  5. Hoffmann O, Zipp F, Weber JR. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation. J Mol Med (Berl). 2009;87(3):753-763. https://doi.org/10.1007/s00109-009-0484-x
  6. Rubio-Perez JM, Morillas-Ruiz JM. Inflammatory process in Alzheimer’s disease, role of cytokines. Scientific World Journal. 2012;ID756357:1-15. https://doi.org/10.1100/2012/756357
  7. Perry RT, Collins JS, Wiener H, Acton R, Go RC. The role of TNF and its receptors in Alzheimer’s disease. Neurobiol Aging. 2001;22(6):873-883. https://doi.org/10.1100/2012/756357
  8. McAlpine FE, Tansey MG. Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer’s disease. J Inflamm Res. 2008;1:29-39. https://doi.org/10.1100/2012/756357
  9. Scott KR, Barrett AM. Dementia syndromes; Evalution and treatment. Expert Rev Neurother. 2007;7(4):407-422. https://doi.org/10.1586/14737175.7.4.407
  10. Rozhnova UA, Alessenko AV. TNF-alpha induced changes in shingomyelin cycle and cholesterol level in rat brain. Europian Cytokine Network. 1998;9(3):458-459.
  11. Engelhardt B. Molecular mechanisms involved in T cell migration across the blood-brain barrier. J Neural Transm. 2006;113(4):477-485. https://doi.org/10.1007/s00702-005-0409-y
  12. Adibhatla RM, Hatcher JF. Altered lipid metabolism in brain injury and disorders. Subcell Biochem. 2008;49:241-268. https://doi.org/10.1007/978-1-4020-8831-5_9
  13. Tweedie D, Sambamurti K, Greig NH. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res. 2007;4(4):378-385. https://doi.org/10.2174/156720507781788873
  14. Tobinick E. Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. CNS Drugs. 2009;23(9):713-725. https://doi.org/10.2165/11310810-000000000-00000
  15. Frankola KA, Greig NH, Luo W, Tweedie D. Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol Disord Drug Targets. 2011;10(3):391-403. https://doi.org/10.2174/187152711794653751
  16. Matveeva IA. Action of dimebon on histamine receptors. Farmakol Toksikol. 1983;46(4):27-29. (In Russ.)
  17. Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, Grigorieva I, Ivanov Y, Sablin S, Zefirov N. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann NY Acad Sci. 2001;939:425-435. https://doi.org/10.1111/j.1749-6632.2001.tb03654.x
  18. Grigor’ev VV, Garibova TL, Voronina TA, Litvinova SA, Bachurin SO. Effects of chronic administration of dimebon on behavior and memory of SAMP 10 mice. Eksp Klin Farmakol. 2009;72(1):52-56. (In Russ.) https://doi.org/10.1016/j.jns.2009.02.170
  19. Ustyugov AA, Shelkovnikova TA, Kokhan VS, Khritankova IV, Peters O, Buchman VL, Bachurin SO, Ninkina NN. Dimebon reduces the levels of aggregated amyloidogenic protein forms in detergent-insoluble fractions in vivo. Bull Exp Biol Med. 2012;152(6):731-733. (In Russ.) https://doi.org/10.1007/s10517-012-1618-7
  20. Lermontova NN, Lukoyanov NV, Serkova TP, Lukoyanova EA, Bachurin SO. Dimebon improves learning in animals with experimental Alzheimer’s disease. Bull Exp Biol Med. 2002;129(6):544-546. (In Russ.) https://doi.org/10.1007/BF02434871
  21. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D. Dimebon investigators. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;19(372):207-215. https://doi.org/10.1016/S0140-6736(08)61074-0
  22. Steele JW, Gandy S. Latrepirdine (Dimebon, a potential Alzheimer therapeutic, regulates autophagy and neuropathology in an Alzheimer mouse mode. Autophagy. 2013;9(4):617-618. https://doi.org/10.4161/auto.23487
  23. Bligh TG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911-917.
  24. Osburg B, Domling D, Schomburg L, Ko YT, Voigt K, Bickel U. Effect of endotoxin on expression of TNF receptors and transport of TNF-alpha at the blood-brain barrier of the rat. Am J Physiol Endocrinol Metab. 2002;283(5):899-908. https://doi.org/10.1152/ajpendo.00436.2001
  25. Alessenko AV, Bugrova AE, Dudnik LB. Connection of lipid peroxide oxidation with sphingomyelin cycle pathway in the development of Alzheimer’s disease. Biochem Soc Transaction. 2004;32(1):144-146. https://doi.org/10.1042/bst0320144
  26. Alessenko AV. Role of sphingomyelin cycle signaling system in Alzheimer’s disease. In book: New Research on Alzheimer’s Disease. NOVA Science, USA; 2006;168-189.
  27. Alessenko AV, Bachurin SO, Gurianova SV, Karatasso Ju, Shevzova EF, Shingarova LN. Tumor necrosis factor-alpha — potential target for neuroprotector dimebon. Biochemistry (Moscow) Supplement. Series B: Biomedical Chemistry. 2015;9(2):188-197. https://doi.org/10.1134/s199075081502002x

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.